BACKGROUND: Serum amyloid A (SAA) induces inflammation and apoptosis in kidney cells and is found to be causing the pathologic changes that are associated with diabetic kidney disease (DKD). Higher serum SAA concentrations were previously associated with increased risk of end-stage renal disease (ESRD) and death in persons with type 2 diabetes and advanced DKD. We explored the prognostic value of SAA in American Indians with type 2 diabetes without DKD or with early DKD. METHODS: SAA concentration was measured in serum samples obtained at the start of follow-up. Multivariate proportional hazards models were employed to examine the magnitude of the risk of ESRD or death across tertiles of SAA concentration after adjustment for traditional risk factors. The C statistic was used to assess the additional predictive value of SAA relative to traditional risk factors. RESULTS: Of 256 participants (mean ± SD glomerular filtration rate [iothalamate] = 148 ± 45 mL/min, and median [interquartile range] urine albumin/creatinine = 39 [14-221] mg/g), 76 developed ESRD and 125 died during a median follow-up period of 15.2 and 15.7 years, respectively. After multivariable proportional hazards regression, participants in the 2 highest SAA tertiles together exhibited a 53% lower risk of ESRD (hazard ratio [HR] 0.47, 95% CI 0.29-0.78), and a 30% lower risk of death (HR 0.70, 95% CI 0.48-1.02), compared with participants in the lowest SAA tertile, although the lower risk of death was not statistically significant. Addition of SAA to the ESRD model increased the C statistic from 0.814 to 0.815 (p = 0.005). CONCLUSIONS: Higher circulating SAA concentration is associated with a reduced risk of ESRD in American Indians with type 2 diabetes.
BACKGROUND:Serum amyloid A (SAA) induces inflammation and apoptosis in kidney cells and is found to be causing the pathologic changes that are associated with diabetic kidney disease (DKD). Higher serum SAA concentrations were previously associated with increased risk of end-stage renal disease (ESRD) and death in persons with type 2 diabetes and advanced DKD. We explored the prognostic value of SAA in American Indians with type 2 diabetes without DKD or with early DKD. METHODS:SAA concentration was measured in serum samples obtained at the start of follow-up. Multivariate proportional hazards models were employed to examine the magnitude of the risk of ESRD or death across tertiles of SAA concentration after adjustment for traditional risk factors. The C statistic was used to assess the additional predictive value of SAA relative to traditional risk factors. RESULTS: Of 256 participants (mean ± SD glomerular filtration rate [iothalamate] = 148 ± 45 mL/min, and median [interquartile range] urine albumin/creatinine = 39 [14-221] mg/g), 76 developed ESRD and 125 died during a median follow-up period of 15.2 and 15.7 years, respectively. After multivariable proportional hazards regression, participants in the 2 highest SAA tertiles together exhibited a 53% lower risk of ESRD (hazard ratio [HR] 0.47, 95% CI 0.29-0.78), and a 30% lower risk of death (HR 0.70, 95% CI 0.48-1.02), compared with participants in the lowest SAA tertile, although the lower risk of death was not statistically significant. Addition of SAA to the ESRD model increased the C statistic from 0.814 to 0.815 (p = 0.005). CONCLUSIONS: Higher circulating SAA concentration is associated with a reduced risk of ESRD in American Indians with type 2 diabetes.
Authors: Margareta Jernås; Jenny Palming; Kajsa Sjöholm; Eva Jennische; Per-Arne Svensson; Britt G Gabrielsson; Max Levin; Anders Sjögren; Mats Rudemo; Theodore C Lystig; Björn Carlsson; Lena M S Carlsson; Malin Lönn Journal: FASEB J Date: 2006-06-05 Impact factor: 5.191
Authors: Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles Journal: J Am Soc Nephrol Date: 2017-01-31 Impact factor: 10.121
Authors: E Jennifer Weil; Gudeta Fufaa; Lois I Jones; Tracy Lovato; Kevin V Lemley; Robert L Hanson; William C Knowler; Peter H Bennett; Berne Yee; Bryan D Myers; Robert G Nelson Journal: Diabetes Date: 2013-04-01 Impact factor: 9.461
Authors: Laura J den Hartigh; Shari Wang; Leela Goodspeed; Yilei Ding; Michelle Averill; Savitha Subramanian; Tomasz Wietecha; Kevin D O'Brien; Alan Chait Journal: PLoS One Date: 2014-09-24 Impact factor: 3.240
Authors: Kathrin Untersteller; Sabine Meissl; Markus Trieb; Insa E Emrich; Adam M Zawada; Michael Holzer; Eva Knuplez; Danilo Fliser; Gunnar H Heine; Gunther Marsche Journal: J Lipid Res Date: 2018-05-22 Impact factor: 5.922
Authors: Brad P Dieter; Rick L Meek; Robert J Anderberg; Sheryl K Cooney; Jen L Bergin; Hongyu Zhang; Viji Nair; Matthias Kretzler; Frank C Brosius; Katherine R Tuttle Journal: PLoS One Date: 2019-02-14 Impact factor: 3.240